Northland Securities Reiterates Buy Rating for Aridis Pharmaceuticals (NASDAQ:ARDS)

Northland Securities reiterated their buy rating on shares of Aridis Pharmaceuticals (NASDAQ:ARDS) in a research note published on Friday, March 29th, AnalystRatings.com reports. Northland Securities currently has a $40.00 price target on the stock.

“We anticipate interim data from AR-301 P3 study in 1Q20, w/ TLR by year-end 2020.”,” Northland Securities’ analyst commented.

ARDS has been the topic of a number of other research reports. Cantor Fitzgerald restated a buy rating and issued a $25.00 price objective on shares of Aridis Pharmaceuticals in a report on Wednesday, December 26th. Zacks Investment Research upgraded Aridis Pharmaceuticals from a sell rating to a hold rating in a report on Monday, January 14th. Maxim Group set a $25.00 price target on Aridis Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, December 12th. Finally, ValuEngine lowered Aridis Pharmaceuticals from a buy rating to a hold rating in a report on Friday, December 21st. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Aridis Pharmaceuticals has a consensus rating of Buy and an average target price of $27.50.

ARDS stock traded down $0.13 during midday trading on Friday, reaching $9.65. The stock had a trading volume of 803 shares, compared to its average volume of 3,522. The firm has a market capitalization of $78.24 million and a P/E ratio of -1.38. Aridis Pharmaceuticals has a 52-week low of $7.59 and a 52-week high of $13.85.

Aridis Pharmaceuticals (NASDAQ:ARDS) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.55) by $0.88. The firm had revenue of $1.39 million during the quarter, compared to analysts’ expectations of $0.30 million. As a group, equities research analysts predict that Aridis Pharmaceuticals will post -2.52 earnings per share for the current year.

Aridis Pharmaceuticals Company Profile

Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.

Recommended Story: What are defining characteristics of a correction?

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.